Virtual Library

Start Your Search

Maria Joao Araujo



Author of

  • +

    P2.04 - Immuno-oncology (ID 167)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.04-79 - High Rate of Immune Related Pneumonitis in Lung Cancer Patients Treated with Anti PD-1 Antibodies (ID 1061)

      10:15 - 18:15  |  Author(s): Maria Joao Araujo

      • Abstract
      • Slides

      Background

      Treatment with anti PD-1/PD-L1 antibodies has demonstrated survival improvement in several malignancies, including non small cell lung cancer (NSCLC), but these therapies are not exempt from risks. Meta-analysis and clinical trials have reported immune related (ir) pneumonitis of any grade in 3-5% of patients treated with anti PD-1/PD-L1 antibodies, including grade 3 or higher in 0.8% to 1.8% of patients.

      Method

      We have retrospectively reviewed clinical reports from 125 cancer patients treated at our center with anti PD-1/PD-L1 antibodies (55 were treated with nivolumab, 27 with pembrolizumab, 33 with atezolizumab, 6 with avelumab, and 4 with durvalumab) from January 2016 to January 2019.

      Result

      Nineteen patients (15.2%) developed ir pneumonitis. Four (21%) patients had recurrent pneumonitis during tapering corticoesteroid dose after an initial improvement and finally died. Patient characteristics are summarized in Table 1. Median time to pneumonitis was 4 months (m) (range 1m to 9m). Twelve patients (9.6% %) had grade 3-5 and 7 patients (5.6 %) grade 1-2 pneumonitis. Nine (7.2 %) patients died from ir pneumonitis, including 4 patients with no tumor progression (1 had received only one cycle, and 3 patients had ongoing tumor response at 10m+, 12m+ and 30m+). Ir pneumonitis was more frequent with nivolumab (any grade 21.8 %, grade 3 or higher 18.2 %, including 7 fatal cases-12.7%-), while no patient treated with atezolizumab developed pneumonitis (Table 2).

      Table 1
      Total 19

      Gender

      Women, n (%)

      7 (36,8%)

      Age

      Median (range)

      63,4 (51-82)

      Cancer type, n (rate)

      NSCLC Adenoca

      NSCLC Squamous

      SCLC

      Mesothelioma

      13 (68,4 %)

      4 (21%)

      1 (5,3%)

      1 (5,3%)

      Line of therapy, n (rate)

      Adjuvant

      First line

      Second or further line

      1 (5,2 %)

      8 (42,1%)

      10 (52,6%)

      Tumor Response, n (rate)

      CR

      PR

      SD

      PD

      NE

      2 (10,5%)

      8 (42,1%)

      5 (26,3%)

      3 (15,8%)

      1 (5,2%)

      table 2
      Drug,n patients treated Any Grade, n (%) Grade 3-5, n (%) Grade 5, n (%)
      Nivolumab, 55 12 (21,8%) 10 (18,2%) 7 (12,7%)
      Pembrolizumab, 27 3 (11,1%) 1 (3,7%) 1 (3,7%)
      Atezolizumab, 33 0 0 0
      Durvalumab, 4 2 (50%) 0 0
      Avelumab, 6 2 (33,3%) 1 (16,7%) 1 (16,7%)
      Total, 125 19 (15,2%) 12 (9,6%) 9 (7,2%)

      Conclusion

      In our experience, ir pneumonitis rate with anti PD-1/PD-L1 antibodies in lung cancer patients was 15.2%, including 7.2% of fatal complications. It suggests that previous clinical trials could have under diagnosed this serious complication. Further studies must be performed in order to specifically assess the rate of pneumonitis in patients treated with anti PD-1 and anti PD-L1 antibodies in lung cancer patients.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.